Phase 3 study of eribulin for locally advanced or metastatic breast cancer
Eisai announced preliminary results from a recently completed Phase 3 study with eribulin mesylate (E7389) in patients with locally advanced or metastatic breast cancer.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.